This subtopic integrates knowledge of biological molecules and cellular pathways with the pathophysiology of diseases, enabling learners to evaluate curren
Topic Synopsis
This subtopic integrates knowledge of biological molecules and cellular pathways with the pathophysiology of diseases, enabling learners to evaluate current and emerging treatments. It focuses on how molecular defects drive physiological disorders and how therapeutic interventions—ranging from conventional drugs to innovative gene and cell therapies—target these mechanisms to restore homeostasis. Mastery of this area equips students with critical skills for medical-related fields and research.
Key Concepts & Core Principles
- Homeostasis: The maintenance of a stable internal environment via negative feedback loops (e.g., thermoregulation, blood glucose control).
- Pathophysiology: The study of how normal physiological processes are altered by disease (e.g., atherosclerosis, diabetes).
- Pharmacology: How drugs interact with the body (pharmacodynamics) and how the body processes drugs (pharmacokinetics – absorption, distribution, metabolism, excretion).
- Diagnostic Techniques: Methods like ELISA, PCR, and medical imaging (X-ray, MRI) used to detect and monitor disease.
- The Immune Response: Innate vs adaptive immunity, including the roles of antibodies, T-cells, and memory cells.
Exam Tips & Revision Strategies
- When answering questions on treatments, always relate the mechanism of action back to the underlying molecular pathology—this demonstrates deep understanding and meets higher-mark band criteria.
- Use named examples of innovative therapies (e.g., CAR-T cell therapy for leukaemia) and critically discuss their real-world application, including cost and accessibility, to strengthen evaluation marks.
- In assignments, structure your response to first explain the biological pathway, then the disease consequence, and finally the treatment, ensuring a logical flow that shows cause-and-effect reasoning.
Common Misconceptions & Mistakes to Avoid
- Confusing the molecular defect with the clinical symptom—for example, stating that cystic fibrosis is caused by mucus build-up rather than the CFTR protein malfunction.
- Overgeneralising future treatments like 'gene therapy' without specifying the delivery method (e.g., viral vectors) or addressing challenges such as off-target effects.
- Failing to distinguish between hereditary and acquired physiological disorders, leading to inappropriate treatment recommendations.
Examiner Marking Points
- Award credit for accurately linking a named biological molecule (e.g., insulin, haemoglobin) to its specific physiological role and detailing how its dysfunction leads to a disease state.
- Credit given for clearly mapping a disrupted metabolic or signaling pathway (e.g., the JAK-STAT pathway) to the clinical manifestations of a disorder and its targeted therapy.
- Marks should be allocated for evaluating the potential of an innovative treatment (e.g., CRISPR gene editing) by comparing its benefits, limitations, and ethical considerations against conventional approaches.